SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (1104)6/28/2003 4:29:33 PM
From: JEB  Read Replies (1) | Respond to of 1137
 
Hi Chris,

Hmm, ...this was a study which used Intron-A instead of Pegintron. The numbers have to be considered in comparison to the old drug. Viral clearance with the Pegintron would be greater.

Also, a 12-month delay on the measure of the viral load is a more true measure for viral clearance than would be at the end of the study since it only takes one or two virus cells hiding in an organ (undetected) to start replicating and create a relapse.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News